Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FAMy: Fedratinib plus CC-486 in Accelerated Phase Myelofibrosis
2024-519227-22-00Phase 2Completed
- Sponsor
- Martin Luther University Halle-Wittenberg
- Start
- Dec 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fedratinib and azacitidine in myeloproliferative disorder (MPD), primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) and 1 more, sponsored by Martin Luther University Halle-Wittenberg. Primary endpoints: Dose-limiting toxicities and maximum tolerated dose of fedratinib + CC-486 (Phase I) and Best response at week 24 (Phase II). Started Dec 2024; status: completed.
02
Drugs
fedratinibazacitidine
03
Conditions
myeloproliferative disorder (MPD)primary myelofibrosis (PMF)post-polycythemia vera myelofibrosis (PPV-MF)post-essential thrombocythemia myelofibrosis (PET-MF)
Beyond the preview
Go deeper on 2024-519227-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519227-22-00.